Basic Research

News Basic Research

• Molecular simulations confirm role of functional rotation in multidrug resistance

  A new molecular simulation technique developed by researchers at RIKEN and Kyoto University has confirmed for the first time the function of the transporter protein AcrB in E. coli multidrug resistance. The result marks a key step in efforts to combat antibiotic resistance, demonstrating the power o more

• Cooperation in diabetes research

  The Max Planck Institute (MPI) of Biochemistry in Martinsried and pharmaceutical company GlaxoSmithKline GmbH & Co. KG (GSK) have signed a research agreement on the development of new drugs for the treatment of type II diabetes. The cooperation agreement, negotiated with the help of technology trans more

• MDxHealth Outlines New Strategy

  MDxHealth, formerly known as OncoMethylome Sciences, announced further details regarding its revised business strategy. For the past several months, MDxHealth’s management has worked very closely with the Board of Directors to define a strategic path to accelerate growth and monetization of the Comp more

White papers Basic Research

• Wyeth 'learns and confirms' in India
  

  Aparna Singh (AS), Program Manager with Frost & Sullivan's Chemical Materials and Foods team caught up with Dr. Michael Kolb (Dr. MK) at Frost & Sullivan's Opportunities in Lifescience Molecules: Global Partnership Summit 2006. This annual summit was held at Goa (India) from 21st -23rd May, 2006. more

• Outsourcing R&D Innovation takes on New Meaning
  

  Innovative drugs are the lifeblood of pharmaceutical companies, but the cost of developing them is rising to unsustainable levels. Pharma executives are already saying that as the economy falters, they foresee bleak prospects and mergers unless their companies get more innovative drugs into their pipelines. The clock is ticking on the race to increase productivity, as key patents worth a projected $30 billion in revenue will expire between 2010 and 2013, opening the floodgates to competition from generics, according to Barbara Ryan, an analyst at Deutsche Bank. This imperative is propelling increased outsourcing of R&D operations as companies trim overcapacity. more

• Improved Performance of the LightCycler®
  

  Real-time reverse transcription-PCR (RT-PCR) is con­sidered the method of choice for any experiments requiring­ sensitive, specific, and reproducible quantification of mRNA molecules of interest. It is an essential tool for basic research, molecular medicine, and biotechnology. more

Publications Basic Research

• Progress in understanding mood disorders: optogenetic dissection of neural circuits

  Abstract Major depression is characterized by a cluster of symptoms that includes hopelessness, low mood, feelings of worthlessness, and inability to experience pleasure. The lifetime prevalence of major depression approaches 20%, yet current treatments are often inadequate both because of assoc more

• Benefits of an Inclusive US Education System

  Presented is a historical perspective of one scientist's journey from war-torn Europe to the opportunities presented by a flexible US educational system. It celebrates the opening of the science establishment that began in the 1950s and its fostering of basic research, and recognizes individuals who more

• Where exactly do basic research findings meet the general public?

  Canadian Journal of Physiology and Pharmacology, Volume 91, Issue 4, Page iii, April 2013. more

Market studies Basic Research

• Medical & Biological Laboratories Co., Ltd. - Strategic SWOT Analysis Review

  Medical & Biological Laboratories Co., Ltd.(MBL) is engaged in the research, development and manufacture of clinical reagents and basic research reagents. It products are marketed to hospitals, research institutions and clinical testing centers. Its subsidiaries include MBL International (MBLI) and more

• Medical & Biological Laboratories Co., Ltd. (4557) - Strategic SWOT Analysis Review

  Medical & Biological Laboratories Co., Ltd.(MBL) is engaged in the research, development and manufacture of clinical reagents and basic research reagents. It products are marketed to hospitals, research institutions and clinical testing centers. Its subsidiaries include MBL International (MBLI) and more

• Becton, Dickinson and Company (BDX) - Product Pipeline Analysis

  Becton, Dickinson and Company (BDX) - Product Pipeline Analysis Summary Becton, Dickinson and Company (BD) is a medical technology company, serving large healthcare institutions, life science researchers and clinical laboratories. The company manufactures and sells medical devices, reagents and in more

Websites Basic Research